Literature DB >> 10911929

Application of artificial enzymes to the problem of cocaine.

P De Prada1, G Winger, D W Landry.   

Abstract

Cocaine mediates its reinforcing and toxic actions through a "loss of function" effect at multiple receptors. The difficulties inherent in blocking a pleiotropic blocker pose a great obstacle for the classical receptor-antagonist approach and have contributed to the failure-to-date to devise specific treatments for cocaine overdose and addiction. As an alternative, we have embarked on an investigation of catalytic antibodies, a programmable class of artificial enzyme, as "peripheral blockers"--agents designed to bind and degrade cocaine in the circulation before it partitions into the central nervous system to exert reinforcing or toxic effects. We synthesized transition-state analogs of cocaine's hydrolysis at its benzoyl ester, immunized mice, prepared hybridomas, and developed the first anti-cocaine catalytic antibodies with the capacity to degrade cocaine to non-reinforcing, non-toxic products. We subsequently identified several families of anti-cocaine catalytic antibodies and found that out most potent antibody, Mab15A10, possessed sufficient activity to block cocaine-induced reinforcement and sudden death in rodent models of addiction and overdose, respectively. With the potential to promote cessation of use, prolong abstinence, and provide a treatment for acute overdose, the artificial enzyme approach comprehensively responds to the problem of cocaine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10911929     DOI: 10.1111/j.1749-6632.2000.tb06681.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase.

Authors:  Chang-Guo Zhan; Fang Zheng; Donald W Landry
Journal:  J Am Chem Soc       Date:  2003-03-05       Impact factor: 15.419

Review 2.  Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases.

Authors:  G A Nevinsky; Valentina N Buneva
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.